Clin2
NCT07061145Possibly a fitRecruiting

TKI treatment and erectile dysfunction in men with CML

Chronic Myelocytic LeukemiaErectile DysfunctionsCVD - Cardiovascular DiseaseTyrosine Kinase Inhibitor

Part of Blood & lymphatic, Cancer, Heart & circulation, Kidney & urinary, Mental health clinical trials.

This study looks at whether tyrosine kinase inhibitors (TKIs), a common treatment for chronic myeloid leukemia (CML), are linked to erectile dysfunction in men. It aims to help patients and doctors understand possible side effects.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
350 people
Ages
18 years to 75 years
Study type
Observational

Who can take part

  • You are male and at least 18 years old, but no older than 75.
  • You have chronic myeloid leukemia (CML) in the early (chronic) phase.
  • You started your first TKI treatment between January 2015 and January 2022.
  • You did not have erectile dysfunction before starting TKI therapy.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06724536Recruiting
Study of gut bacteria and TKIs in chronic myeloid leukemia

This trial looks at how gut bacteria affect the way chronic myeloid leukemia (CML) patients respond to tyrosine kinase inhibitor (TKI) medications. It may help doctors understand why some people have better outcomes than others.

Torino
NCT07091019Recruiting
CML patient experience study on standard TKI therapy

This study tracks the experiences and health outcomes of people with chronic myeloid leukemia (CML) who are taking approved first or second line tyrosine kinase inhibitor (TKI) medicines. It helps doctors learn how these treatments work in everyday care.

Birmingham, Alabama
NCT07200882Not yet recruiting
How TKI treatment affects thyroid in CML patients

This trial looks at how a targeted therapy called TKI (tyrosine kinase inhibitor) affects thyroid function in patients newly diagnosed with chronic myeloid leukemia (CML). It aims to understand any changes in the thyroid gland during treatment.

NCT04835584Recruiting· Phase 1/Phase 2
Testing KRT-232 with a TKI for CML that didn’t respond

This trial studies a new drug (KRT-232) combined with a standard CML “TKI” medicine to treat chronic myeloid leukemia (CML) that is resistant or not tolerated after at least one prior TKI. It may help people whose leukemia hasn’t controlled as expected on current treatments.

Birmingham, Alabama
NCT07773103Recruiting
Tadalafil and blood vessel markers for erectile dysfunction

This study tests whether tadalafil, a daily pill for erectile dysfunction, improves blood vessel health and erectile function. It may help men with erectile dysfunction caused by blood vessel problems.

Cairo
NCT07413263Not yet recruiting
Effect of CML drugs on blood sugar and cholesterol

This study looks at how certain CML treatments called tyrosine kinase inhibitors affect blood sugar and cholesterol levels in people with chronic myeloid leukemia. It may help understand if these drugs change metabolism.

Hear when a new Tyrosine Kinase Inhibitor trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.